{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:ixoberogene soroparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:bevufenogene nofeparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03517085: Phase 1/Phase 2 Interventional Completed GSD1
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04566445: Phase 2 Interventional Terminated Dry Age-related Macular Degeneration
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:cevaretigene ritoparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03223194: Phase 1 Interventional Terminated Crigler-Najjar Syndrome
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03641703: Phase 1/Phase 2 Interventional Terminated Hemophilia B
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02695160: Phase 1 Interventional Terminated Hemophilia B
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:ranuzifigene civaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03041324: Phase 1/Phase 2 Interventional Terminated Mucopolysaccharidosis II
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE